Shop by goal
Popular compounds
Research resources
Recently viewed
Retatrutide vs Tirzepatide: Triple vs Dual Agonist, Compared
Retatrutide is an investigational triple agonist (GIP + GLP-1 + glucagon); tirzepatide is an FDA-approved dual agonist (GIP + GLP-1). In their separate trials, retatrutide reached ~24.2% mean weight reduction at 48 weeks (Phase 2, highest dose, not yet plateaued) and tirzepatide ~22.5% at 72 weeks (SURMOUNT-1, highest dose). They have never been compared head-to-head , and only tirzepatide is approved.
No head-to-head trial exists. The figures below come from separate studies with different populations, durations, doses and endpoints. Cross-trial percentages are indicative only — they are not evidence that one compound outperforms another. All data is presented for research context; nothing here is medical or dosing guidance.
On this page
At a glance
Mechanism: triple vs dual agonism
Both molecules are incretin-based, but retatrutide adds a third arm.
Tirzepatide — dual
Activates the GIP and GLP-1 receptors. The combination drives the appetite and glycemic effects behind its trial results.
Retatrutide — triple
Adds glucagon-receptor agonism on top of GIP/GLP-1. In theory the glucagon arm raises energy expenditure, but the individual receptor contributions are not yet disentangled in humans.
Adding a receptor target is a hypothesis, not a guarantee of superiority. Retatrutide’s glucagon arm is exactly why its long-term safety and metabolic profile still need Phase 3 confirmation.
What the trials showed
Because trial length, dose ladders and populations differ, the honest read is: both produce large reductions in their own trials, retatrutide’s early numbers are striking, and only a direct trial could rank them.
Regulatory status
Tirzepatide is FDA-approved (marketed as Mounjaro for type 2 diabetes and Zepbound for weight management). Retatrutide remains investigational with no approval anywhere; it is a research compound only. That gap matters more than any percentage: approval reflects completed safety review that retatrutide has not yet cleared.
Side-effect profiles
Both are dominated by gastrointestinal events (nausea, diarrhoea, constipation, vomiting) that are dose-dependent and tend to ease with slower titration in their trials. Retatrutide trials also noted dose-related increases in heart rate and, for the glucagon arm, attention to glycemic and hepatic parameters. Tirzepatide’s profile is the better characterised of the two simply because it has far more post-approval data.
Research takeaway
Retatrutide & tirzepatide, lab-direct
New-U supplies both as >99% HPLC-verified research compounds with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Related reading
Frequently asked questions
No trial has compared them directly, so this cannot be answered from evidence. In separate trials retatrutide reached ~24.2% at 48 weeks (Phase 2) and tirzepatide ~22.5% at 72 weeks (SURMOUNT-1), but different designs make cross-trial ranking unreliable. Tirzepatide is approved; retatrutide is investigational. Research context only.
Retatrutide is a triple agonist (GIP, GLP-1 and glucagon receptors) and is still in Phase 3 trials. Tirzepatide is a dual agonist (GIP and GLP-1) and is FDA-approved. The extra glucagon arm is retatrutide’s defining feature.
No. Tirzepatide is FDA-approved (Mounjaro and Zepbound). Retatrutide has no approval anywhere and remains an investigational research compound.
Both are dominated by dose-dependent gastrointestinal effects. Retatrutide trials also noted heart-rate increases and attention to glycemic/hepatic parameters from the glucagon arm; tirzepatide’s profile is better characterised because of post-approval data.
All figures are laboratory-preparation reference points, not dosing guidance. New-U Research Compounds supplies bacteriostatic water and research compounds strictly for laboratory research use only — not for human consumption .
Research-grade · >99% HPLC purity · COA per lot
Buy Retatrutide from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io